What Bontril Treats: Main Uses and Benefits

Phendimetrazine (Bontril) is specifically indicated for use in the clinical management of exogenous obesity. Its application is defined as a short-term adjunct in a comprehensive weight reduction regimen. The medication's role is to help patients work toward their weight reduction goals when they have not responded adequately to diet and exercise alone.

Bontril is commonly used to address symptoms related to heightened physiological activity, specifically the persistent, difficult-to-manage feelings of excessive hunger drive and food cravings. By helping to ease this symptom burden, Phendimetrazine supports patients during the challenging initial phases of dietary change.

It is relevant in conditions characterized by periods of heightened symptoms (such as severe obesity) where the patient has an initial Body Mass Index ( BMI) of 30 kg/m^2 or greater. It is also applied when the BMI is 27 kg/m^2 or greater in situations involving associated health risks, such as controlled hypertension or Type 2 diabetes mellitus. The achieved weight loss contributes to easing the overall symptom load and may assist with managing the risk associated with these weight-related comorbidities.

Quick Fact: Relief for Excessive Hunger

The medication may assist with maintaining functional stability by helping patients adhere to the strict limitations of a reduced-calorie eating plan.

Regulatory References

1. DailyMed official labeling information, managed by the NIH

Who can and cannot use Bontril?

The eligibility for using Bontril (Phendimetrazine) is strictly defined by regulatory authorities and is determined by a patient's health status, age, and Body Mass Index (BMI).

Eligibility Criteria

Bontril is indicated only for adults who meet specific BMI thresholds, serving as a short-term adjunct to a weight reduction regimen. Patients must have an initial BMI of 30 kg/m^2 or greater, or a BMI of 27 kg/m^2 or greater when co-morbidities like controlled hypertension or Type 2 diabetes mellitus are present.

Absolute Contraindications (Must Not Use)

Use is strictly prohibited (contraindicated) for patients with the following conditions, as these pose a significant health risk:

• Cardiovascular Disease: Including advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension, or pulmonary hypertension.
• Other Conditions: Including hyperthyroidism, glaucoma, agitated states, or a history of drug abuse.
• Concomitant Use: It must not be used concurrently with other CNS stimulants or within 14 days of taking a Monoamine Oxidase Inhibitor (MAOI).
• Reproductive Status: The medication is contraindicated in women who are pregnant or nursing.

Age-Related Restrictions

Safety and effectiveness have not been established in pediatric patients. Use is not recommended in children under 12 years (IR) or those less than 17 years (ER). Geriatric patients require cautious dose selection due to potential age-related organ impairment.

Bontril (phendimetrazine) is a sympathomimetic amine and central nervous system (CNS) stimulant, meaning it affects the nervous system in a manner similar to amphetamines. Due to its action on neurotransmitters, it has several clinically significant interactions with other drugs.

Contraindicated Combinations (Do Not Use Together)

Monoamine Oxidase Inhibitors (MAOIs): Concurrent use or use within 14 days of taking an MAOI (such as isocarboxazid, phenelzine, or selegiline) is strictly contraindicated. This combination poses a high risk of a hypertensive crisis (dangerously high blood pressure) due to exaggerated sympathomimetic effects.

Other Stimulants and Anorectic Agents: Combining Bontril with other CNS stimulants or appetite suppressants (e.g., phentermine, amphetamines) is generally avoided. This can increase the risk of serious cardiovascular side effects like high blood pressure, rapid heart rate, and potential pulmonary hypertension or valvular heart disease.

Other Significant Interactions

Antihypertensive Medications: Bontril may decrease the therapeutic effect of medications used to treat high blood pressure (antihypertensives), such as beta-blockers or ACE inhibitors, due to its own tendency to elevate blood pressure.

Antidepressants (SSRIs/SNRIs): Combining Bontril with certain antidepressants, including Selective Serotonin Reuptake Inhibitors (SSRIs) like sertraline or Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) like venlafaxine, requires caution. This combination may increase the risk of a rare but serious condition called serotonin syndrome (symptoms can include agitation, hallucinations, rapid heart rate, and confusion), as well as enhanced stimulant side effects.

Alcohol: Consumption of alcohol while taking Bontril may lead to an increase in adverse CNS effects.

Bontril contains phendimetrazine, a phenylalkylamine sympathomimetic amine. This compound functions primarily as a norepinephrine-dopamine releasing agent (NDRA) within the central nervous system, particularly targeting the hypothalamus. The molecule is also metabolized to its active form, phenmetrazine, which contributes to the overall effect.

Phendimetrazine, and its metabolite, enter presynaptic neurons and induce the non-vesicular release of the monoamines norepinephrine (NE) and dopamine (DA) from the nerve terminals into the synaptic cleft. This action increases the concentration of these neurotransmitters available to bind to post-synaptic adrenergic and dopaminergic receptors. The binding of NE to alpha-adrenergic receptors in the hypothalamus, a region governing energy balance, initiates a signaling cascade. This increased catecholaminergic neurotransmission leads to a physiological consequence of reduced signaling associated with food-seeking behavior and a generalized central nervous system stimulation, which includes an elevation of systemic blood pressure.

How to Use Bontril (Phendimetrazine Tartrate) — Official Administration Guidelines

Bontril (phendimetrazine tartrate) is administered strictly via the oral route and is indicated for use as a short-term adjunct in a comprehensive weight reduction regimen. The medication is available in two main official formulations, which dictate the specific administration schedule.

---

Official Dosing and Administration Schedule

Formulation	Standard Dosing Regimen	Timing and Administration Constraint
Immediate-Release (IR) 35 mg Tablet	35 mg two or three times a day. The maximum recommended dose is 70 mg (two tablets) per administration, three times daily.	Administered one hour before meals.
Extended-Release (ER) 105 mg Capsule	One 105 mg capsule, once a day.	Administered 30 to 60 minutes before the morning meal and must be swallowed whole.

---

Procedural and Population-Specific Rules

Treatment duration is limited, typically spanning only a few weeks. The continuation of therapy is contingent upon the patient achieving a satisfactory initial weight loss (at least 4 pounds) within the first four weeks of use. Use must also be discontinued if a patient develops tolerance to the anorectic effect of the medication.

For older adults, dose selection should be performed cautiously, and typically begins at the lower end of the established dosing range. Safety and effectiveness of phendimetrazine have not been established for use in pediatric patients under 17 or 18 years of age, depending on the specific formulation.

Research Evidence / Overview of Studies for Bontril

---

Evidence for Short-Term Use in Exogenous Obesity

Research exploring this medication was evaluated in adult populations diagnosed with exogenous obesity. The core evidence primarily comes from short-term Randomized Controlled Trials (RCTs). These studies monitored whether the addition of the medication, alongside a reduced-calorie eating plan, was associated with differences in outcomes compared to using a placebo (an inactive substance) alongside the same eating plan.

Researchers monitored primary measurements in these studies, including changes in body weight and whether participants met certain weight reduction thresholds over defined time intervals. Studies reported how symptoms evolved in the observed populations over the study periods, which typically were limited to a few weeks. Findings describe patterns of measured weight loss when compared to groups receiving placebo alongside a reduced-calorie diet.

It is important to understand that the results apply only to the populations studied and reflect patterns observed in the studies over a very short duration. Follow-up durations were limited in these core trials, and therefore, research exploring short-term symptom changes does not offer insight into long-term outcomes.

---

Research on Secondary Metabolic Outcomes

Beyond the primary focus on weight management, some research examined secondary outcomes related to systemic or functional imbalance. These assessments included monitoring factors such as blood pressure and lipid profiles (cholesterol and related fats) in the study participants.

Changes in these markers were recorded at the same time as the weight reduction measured in the studies. Research describes the short-term changes that were monitored concurrently with the reduced-calorie diet and weight loss.

---

What Scientific Uncertainty Remains

One of the primary limitations is that the follow-up durations were limited, and the evidence largely consists of research exploring short-term symptom changes. This means there is limited information for long-term outcomes across all patient groups. In addition, some of the supporting evidence comes from older reports where sample sizes were modest, and the evidence quality varies across studies.

Common questions about Bontril (FAQ)

Q: Is Bontril considered a controlled substance?

A: Yes, Bontril (phendimetrazine) is classified by regulatory bodies as a Schedule III controlled substance. This classification is due to the formally recognized potential for abuse and dependence associated with the medication.

Q: Is it common to feel jittery or restless when taking Bontril?

A: Official product information notes that restlessness and overstimulation are documented adverse reactions affecting the central nervous system. These effects are related to the drug’s stimulant nature.

Q: What are the most commonly reported side effects of Bontril?

A: Commonly reported effects listed in official documents are related to the drug's stimulant actions, such as increased heart rate or blood pressure, tremor, and difficulty sleeping. Gastrointestinal effects such as dry mouth, nausea, and headache are also frequently reported.

Q: Does Bontril cause insomnia or difficulty sleeping?

A: Official labeling includes insomnia and general difficulty sleeping as documented adverse reactions. These effects are primarily due to the drug's stimulating actions on the central nervous system.

Q: What should be done if I experience severe headache while on Bontril?

A: Official patient information indicates that medical help should be sought immediately for very serious side effects. A severe headache is noted as a symptom that warrants prompt medical attention to evaluate any underlying condition.

Q: Can Bontril cause mood changes or anxiety?

A: Official documents list mental or mood changes, nervousness, and agitation as possible effects. These are noted as signs that may warrant medical evaluation.

Q: What kinds of physical symptoms are signs of a serious interaction with Bontril?

A: Warnings about serious cardiovascular events note physical symptoms like chest pain, fainting, difficulty breathing, or swelling of the legs and ankles. Additionally, neurological symptoms such as sudden weakness or a severe headache are noted as symptoms that require prompt consultation with a healthcare professional.

Q: Do I need to taper off Bontril when stopping use?

A: Abrupt discontinuation following prolonged use at high dosages has been associated in official reports with withdrawal-type symptoms, specifically extreme fatigue and mental depression. Discontinuation is generally managed in consultation with a healthcare professional.

Q: Can Bontril lead to feelings of dependence?

A: Yes, regulatory labeling formally recognizes the potential for both abuse and dependence. This is the reason why the drug is classified as a controlled substance.

Q: Are there foods or drinks to avoid while using Bontril?

A: Official patient information contains a caution regarding the use of large amounts of beverages containing caffeine, such as coffee, tea, or colas, as well as nonprescription products that contain caffeine. This is noted because caffeine may increase the severity of the medication's side effects.

Q: Is it safe to drink coffee or caffeine while taking Bontril?

A: Official patient information contains a caution regarding the use of large amounts of caffeine-containing beverages. This precaution is noted because caffeine can enhance the drug's stimulant effects, which may increase the risk of side effects.

Q: Does Bontril interact with common over-the-counter cold medicines?

A: Official labeling indicates that combining Bontril with certain over-the-counter cold and flu medications that contain sympathomimetic agents may increase the risk of cardiovascular side effects, such as increased blood pressure and heart rate.

Q: Is Bontril appropriate for use by elderly patients?

A: Official guidelines advise that dose selection for older adults should be cautious. Dosing typically begins at the lower end of the established range due to the greater likelihood of age-related reductions in organ function.

Q: Is it common to feel dry mouth while taking Bontril?

A: Dry mouth is listed in official documents as one of the documented adverse reactions associated with the use of the drug. It is a common complaint in the gastrointestinal category of side effects.

Q: Is there a maximum time someone can be prescribed Bontril for?

A: Bontril is only indicated for use as a short-term adjunct to a weight reduction regimen, typically spanning only a few weeks. Its short-term indication is reflected in the official prescribing information.

Q: What type of monitoring is required when starting Bontril?

A: Due to the potential for serious cardiovascular effects, such as elevated blood pressure and increased heart rate, official prescribing information indicates that medical monitoring of these systems is necessary during the use of the medication.

Q: Is it true that Bontril may cause changes in taste?

A: Official documents sometimes list an alteration or unpleasant taste as a possible gastrointestinal adverse reaction.

Q: Does Bontril have any known interactions with alcohol?

A: Official prescribing information indicates that concurrent use of alcohol with Bontril may lead to an increase in adverse central nervous system (CNS) effects.

Q: Is it possible to split or crush the Bontril tablets?

A: The Extended-Release (ER) capsule formulation is specifically instructed to be swallowed whole and not crushed, chewed, or broken, as this can affect the way the medication is released. This restriction does not apply to the Immediate-Release (IR) tablet.

Q: Does taking Bontril affect blood sugar levels?

A: Official precautions note that the insulin requirements for patients with diabetes mellitus may be altered in connection with the use of the drug. This effect is coupled with the required concomitant dietary regimen.

Q: Is it safe to drive or operate machinery while taking Bontril?

A: Due to its effects on the central nervous system, official labeling includes a caution that the drug may impair the ability to perform potentially hazardous activities, such as driving or operating machinery.

Q: Are there pediatric studies for the use of Bontril?

A: Official labeling states that the safety and effectiveness of Bontril for pediatric patients have not been established in studies. Use is generally not recommended for children under the age of 17.

Q: How does Bontril interact with thyroid medications?

A: Official prescribing information lists hyperthyroidism, a condition involving an overactive thyroid, as a condition that strictly prohibits the use of Bontril.

Q: What are the reasons someone might need to stop taking Bontril suddenly?

A: The medication must be discontinued if a patient develops tolerance to the anorectic effect. Additionally, the development of serious symptoms, such as chest pain, difficulty breathing, or severe headache, are described as reasons for discontinuation and require consultation with a healthcare professional.

Q: Does Bontril affect how the kidneys function?

A: Official information advises that caution is necessary when the medication is administered to patients with renal impairment, which relates to kidney function.

Q: Can Bontril cause constipation or other digestive issues?

A: Official labeling lists adverse reactions on the gastrointestinal system, including dry mouth, nausea, and constipation.

Q: What is the information available on Bontril use during pregnancy?

A: Bontril is strictly contraindicated in women who are pregnant or nursing. Official information states that safe use in pregnancy has not been established and weight loss during pregnancy is generally not considered beneficial.

Q: Does the efficacy of Bontril change over time?

A: Official prescribing information indicates that tolerance to the anorectic effect of the medication can develop. If this happens, it is a required reason for the drug to be discontinued.

Q: Does Bontril require a special kind of prescription refill?

A: As Bontril is a Schedule III controlled substance, its classification means that federal regulations apply to the amount that can be prescribed at one time and the number of times the prescription can be refilled.

Official Storage and Disposal Requirements for Bontril (Phendimetrazine Tartrate)

Official regulatory information defines specific requirements for storing and disposing of Bontril, a Schedule III controlled substance.

Storage Conditions

Bontril must be stored at controlled room temperature, typically 20 C to 25 C (68 F to 77 F). The medication must be protected from moisture and kept in a tightly closed, light-resistant container. It is mandatory to store the medicine out of the reach of children and use a child-resistant closure.

Disposal Protocol

Due to the risk of diversion associated with controlled substances, the official guidance recommends using an approved drug take-back program (such as collection sites or mail-back envelopes) for unused or expired tablets. If a take-back option is unavailable, the medication must be rendered unusable by mixing it with an undesirable substance, such as dirt or used coffee grounds, before sealing and discarding it in the household trash. Do not keep outdated medicine.